Talk to us01 / Our approach
Discovery is accelerating.
Translation is still the bottleneck.
Promising programs stall when biology, modality, rights, CMC, clinical strategy and leadership are treated as separate problems.
SCROLL
The category error
The market often writes off a target when only one therapeutic configuration failed.
A failed experiment can close a chapter. It should not silently close the entire biology.
OBSERVEREASSESSPROVE
The re-underwriting moment
01 / 03
The target failed.
Markets compress a specific clinical result into a broad category judgment. The shorthand travels faster than the evidence.
A verdict is not a mechanism.02 / 03
One configuration was tested.
Target, modality, indication, delivery and patient context formed one experiment—not every possible therapeutic expression of the biology.
Target × modality × indication × delivery03 / 03
What materially changed?
Colara looks for the decisive difference: the new construct, biological insight or development path that can support one fair next test.
Advance with proof—or stop with clarity.The opportunity
Not rescuing failed science.
Finding where the verdict is broader than the evidence.
- 01Re-underwrite the original decision.
- 02Design the next decisive proof.
- 03Secure differentiated rights before the story gets crowded.